Lamivudine impurity A RS
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 598257

CAS#: 173602-25-0

Description: Lamivudine impurity A RS is a bioactive chemical.


Chemical Structure

img
Lamivudine impurity A RS
CAS# 173602-25-0

Theoretical Analysis

MedKoo Cat#: 598257
Name: Lamivudine impurity A RS
CAS#: 173602-25-0
Chemical Formula: C8H9N3O4S
Exact Mass: 243.0314
Molecular Weight: 243.23
Elemental Analysis: C, 39.50; H, 3.73; N, 17.28; O, 26.31; S, 13.18

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Lamivudine impurity A RS; Lamivudine impurity A; Lamivudine specified impurity A;

IUPAC/Chemical Name: 5-(4-amino-2-oxopyrimidin-1(2H)-yl)-1,3-oxathiolane-2-carboxylic acid

InChi Key: PIIRVEZNDVLYQA-UHFFFAOYSA-N

InChi Code: InChI=1S/C8H9N3O4S/c9-4-1-2-11(8(14)10-4)5-3-16-7(15-5)6(12)13/h1-2,5,7H,3H2,(H,12,13)(H2,9,10,14)

SMILES Code: O=C(C1OC(N2C=CC(N)=NC2=O)CS1)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 243.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kurita T, Kitaichi T, Nagao T, Miura T, Kitazono Y. Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in Japan. Pharmacoepidemiol Drug Saf. 2014 Apr;23(4):372-81. doi: 10.1002/pds.3588. Epub 2014 Mar 3. PubMed PMID: 24590575; PubMed Central PMCID: PMC4230469.

2: Weller S, Chen S, Borland J, Savina P, Wynne B, Piscitelli SC. Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food. J Acquir Immune Defic Syndr. 2014 Aug 1;66(4):393-8. doi: 10.1097/QAI.0000000000000193. PubMed PMID: 24798770.

3: Casado JL, Bañón S. Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection. Expert Rev Clin Pharmacol. 2015;8(6):709-18. doi: 10.1586/17512433.2015.1090873. Review. PubMed PMID: 26517111.

4: Fernandez-Montero JV, Barreiro P, Labarga P, De Mendoza C, Soriano V. Dolutegravir, abacavir and lamivudine as HIV therapy. Expert Opin Pharmacother. 2014 May;15(7):1051-7. doi: 10.1517/14656566.2014.913023. Review. PubMed PMID: 24754315.

5: Liu L, Yan Y, Zhou J, Huang LW, He CP, Ling K, Zhou HC, Wen QM, Wang XM. Curative effect of combined lamivudine, adefovir dipivoxil, and stem cell transplantation on decompensated hepatitis B cirrhosis. Genet Mol Res. 2014 Feb 21;13(4):9336-42. doi: 10.4238/2014.February.21.13. PubMed PMID: 24634299.

6: Mukherjee A, Singla M, Velpandian T, Sirohiwal A, Vajpayee M, Singh R, Kabra SK, Lodha R. Pharmacokinetics of nevirapine, stavudine and lamivudine in Indian HIV-infected children receiving generic fixed dose combinations. Indian Pediatr. 2014 Mar;51(3):191-7. PubMed PMID: 24736906.

7: Shekarchi M, Pourfarzib M, Akbari-Adergani B, Mehramizi A, Javanbakht M, Dinarvand R. Selective extraction of lamivudine in human serum and urine using molecularly imprinted polymer technique. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Jul 15;931:50-5. doi: 10.1016/j.jchromb.2013.04.041. Epub 2013 May 21. PubMed PMID: 23764731.

8: Aghasadeghi MR, Heidari H, Sadat SM, Irani S, Amini S, Siadat SD, Fazlhashemy ME, Zabihollahi R, Atyabi SM, Momen SB, Khosraavy MS, Davari M, Darvish Mohammadi T, Doroudian M, Ardestani MS. Lamivudine-PEGylated chitosan: a novel effective nanosized antiretroviral agent. Curr HIV Res. 2013 Jun;11(4):309-20. PubMed PMID: 23808639.

9: Piana C, Zhao W, Adkison K, Burger D, Jacqz-Aigrain E, Danhof M, Della Pasqua O. Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children. Br J Clin Pharmacol. 2014 May;77(5):861-72. doi: 10.1111/bcp.12247. PubMed PMID: 24118070; PubMed Central PMCID: PMC4004406.

10: Hassan S, Amer S, Zervos M. Tropical spastic paraparesis treated with Combivir (lamivudine-zidovudine). J Clin Neurosci. 2013 May;20(5):759-60. doi: 10.1016/j.jocn.2012.05.048. Epub 2013 Mar 9. PubMed PMID: 23477875.

11: Thompson AB, Wynn BA, O Akerele D, A Rostad C, Anderson EJ, Camacho-Gonzalez AF, Spearman P, Chakraborty R. Acute pancreatitis associated with dolutegravir and lamivudine/abacavir administration. AIDS. 2015 Jan 28;29(3):390-2. doi: 10.1097/QAD.0000000000000542. PubMed PMID: 25686687.

12: Fok BS, Gardner S, Piscitelli S, Chen S, Chu TT, Chan JC, Tomlinson B. Pharmacokinetic properties of single-dose lamivudine/adefovir dipivoxil fixed-dose combination in healthy Chinese male volunteers. Clin Ther. 2013 Jan;35(1):68-76. doi: 10.1016/j.clinthera.2012.12.001. Epub 2012 Dec 28. PubMed PMID: 23274144.

13: Piana C, Zhao W, Adkison K, Burger D, Jacqz-Aigrain E, Danhof M, Della Pasqua O. A model-based approach for the evaluation of once daily dosing of lamivudine in HIV-infected children. Br J Clin Pharmacol. 2014 May;77(5):852-60. doi: 10.1111/bcp.12246. PubMed PMID: 24118047; PubMed Central PMCID: PMC4004405.

14: Vourvahis M, Davis J, Langdon G, Layton G, Fang J, Choo HW, Hansson AG, Tawadrous M. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine. Antivir Ther. 2013;18(6):745-54. doi: 10.3851/IMP2566. Epub 2013 Apr 4. PubMed PMID: 23558061.

15: Jung N, Lehmann C, Rubbert A, Schömig E, Fätkenheuer G, Hartmann P, Taubert D. Organic cation transporters OCT1 and OCT2 determine the accumulation of lamivudine in CD4 cells of HIV-infected patients. Infection. 2013 Apr;41(2):379-85. doi: 10.1007/s15010-012-0308-8. Epub 2012 Aug 9. PubMed PMID: 22875535.

16: Han Z, Shi Y, Zhu J, Chen Y, Yin F, Xia L, Luo G, Gao Z, Liu J, Jia G, Li C, Zhou X, Han Y. Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis. J Viral Hepat. 2013 Apr;20 Suppl 1:58-64. doi: 10.1111/jvh.12065. PubMed PMID: 23458526.

17: Vangelotti AM, Araujo Júnior E, Simões J, Amed AM, Nakamura MU, Júnior LK. Chronic action of lamivudine and ritonavir on maternal and fetal liver and kidney of albino pregnant rats (Rattus norvegicus albinus, Rodentia, Mammalia): morphological and biochemical aspects. Clin Exp Obstet Gynecol. 2015;42(4):523-8. PubMed PMID: 26411225.

18: Li X, Liu B, Sun Y, Chen H, Chen H, Zhang H, Zhang Q, Ding Y. Single-dose pharmacokinetic properties, bioavailability, and tolerability of two lamivudine 100-mg tablet formulations: a randomized crossover study in healthy Chinese male subjects. Clin Ther. 2013 Oct;35(10):1546-56. doi: 10.1016/j.clinthera.2013.07.431. Epub 2013 Sep 5. PubMed PMID: 24011635.

19: Caso MF, D'Alonzo D, D'Errico S, Palumbo G, Guaragna A. Highly Stereoselective Synthesis of Lamivudine (3TC) and Emtricitabine (FTC) by a Novel N-Glycosidation Procedure. Org Lett. 2015 Jun 5;17(11):2626-9. doi: 10.1021/acs.orglett.5b00982. Epub 2015 May 12. PubMed PMID: 25965958.

20: Wang G, Liu Y, Qiu P, Zhou SF, Xu L, Wen P, Wen J, Xiao X. Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance. Drug Des Devel Ther. 2015 Jun 2;9:2839-46. doi: 10.2147/DDDT.S73150. eCollection 2015. PubMed PMID: 26082614; PubMed Central PMCID: PMC4459610.